Collaborative Heterogeneity-Aware OS Scheduler for Asymmetric Multicore Processors

Funding: This work is supported in part by the China Postdoctoral Science Foundation (Grant No. 2020TQ0169), the ShuiMu Tsinghua Scholar fellowship (2019SM131), National Key R&D Program of China (2020AAA0105200), National Natural Science Foundation of China (U20A20226), Beijing Natural Science Foundation (4202031), Beijing Academy of Artificial Intelligence BAAI), the UK EPSRC grants Discovery: Pattern Discovery and Program Shaping for Manycore Systems (EP/P020631/1). This work is also supported by the Royal Academy of Engineering under the Research Fellowship scheme.Asymmetric multicore processors (AMP) offer multiple types of cores under the same programming interface. Extracting the full potential of AMPs requires intelligent scheduling decisions, matching each thread with the right kind of core, the core that will maximize performance or minimize wasted energy for this thread. Existing OS schedulers are not up to this task. While they may handle certain aspects of asymmetry in the system, none can handle all runtime factors affecting AMPs for the general case of multi-threaded multi-programmed workloads. We address this problem by introducing COLAB, a general purpose asymmetry-aware scheduler targeting multi-threaded multi-programmed workloads. It estimates the performance and power of each thread on each type of core and identifies communication patterns and bottleneck threads. With this information, the scheduler makes coordinated core assignment and thread selection decisions that still provide each application its fair share of the processor’s time. We evaluate our approach using both the GEM5 simulator on four distinct big.LITTLE configurations and a development board with ARM Cortex-A73/A53 processors and mixed workloads composed of PARSEC and SPLASH2 benchmarks. Compared to the state-of-the art Linux CFS and AMP-aware schedulers, we demonstrate performance gains of up to 25% and 5% to 15% on average,together with an average 5% energy saving depending on the hardware setup.PostprintPeer reviewe

Stroke risk evaluation for patients with atrial fibrillation : Insights from left atrial appendage

Left atrial appendage (LAA) is believed to be a common site of thrombus formation in patients with atrial fibrillation (AF). However, the commonly-applied stroke risk stratification model (such as. CHA2DS2-VASc score) does not include any structural or hemodynamic features of LAA. Recent studies have suggested that it is important to incorporate LAA geometrical and hemodynamic features to evaluate the risk of thrombus formation in LAA, which may better delineate the AF patients for anticoagulant administration and prevent strokes. This review focuses on the LAA-related factors that may be associated with thrombus formation and cardioembolic events.</p

Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma

Ferroptosis is a newly characterized form of iron-dependent non-apoptotic cell death, which is closely associated with cancer progression. However, the functions and mechanisms in regulation of escaping from ferroptosis during hepatocellular carcinoma (HCC) progression remain unknown. In this study, we reported that the RNA binding motif single stranded interacting protein 1 (RBMS1) participated in HCC development，and functioned as a regulator of ferroptosis. Clinically, the downregulation of RBMS1 occurred in HCC tissues, and low RBMS1 expression was associated with worse HCC patients survival. Mechanistically, RBMS1 overexpression inhibited HCC cell growth by attenuating the expression of glutathione peroxidase 4 (GPX4)and further facilitated ferroptosis in vitro and in vivo. More importantly, a novel circIDE (hsa_circ_0000251) was identified to elevate RBMS1 expression via sponging miR-19b-3p in HCC cells. Collectively, our findings established circIDE/miR-19b-3p/RBMS1 axis as a regulator of ferroptosis, which could be a promising therapeutic target and prognostic factor